299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03522831
(ClinicalTrials.gov)
May 1, 201819/3/2018CF BronchodilationA Double-blind Placebo-controlled Crossover Study to Assess the Effects of Bronchodilation on Dyspnea, Ventilatory Responses, and Exercise Tolerance in Adults With Cystic FibrosisLung Diseases;Cystic FibrosisDrug: Salbutamol;Drug: PlaceboUniversity of British ColumbiaNULLRecruiting19 YearsN/AAll20N/ACanada
2EUCTR2015-001317-28-NL
(EUCTR)
30/07/201519/05/2015A B2-agonist as a CFTR activator in CF - Part 2A B2-agonist as a CFTR activator in CF - Part 2 - ABBA 2 Cystic fibrosis;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]Trade Name: SalbutamolUMC UtrechtNULLNot RecruitingFemale: yes
Male: yes
Phase 2Netherlands
3EUCTR2014-000057-37-NL
(EUCTR)
30/04/201412/02/2014Bronchodilcation as a CFTR activator in CFA B2-agonist as a CFTR activator in CF - ABBA study Cystic Fibrosis;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]Product Name: Salbutamol
Product Code: R03AC02
INN or Proposed INN: SALBUTAMOL
Product Name: Salbutamol
Product Code: R03CC02
INN or Proposed INN: SALBUTAMOL
University Medical Centre UtrechtNULLNot RecruitingFemale: yes
Male: yes
Phase 2Netherlands
4NCT01880723
(ClinicalTrials.gov)
May 200915/6/2013Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic FibrosisModifying Genes in Cystic Fibrosis: The Beta-2 Adrenergic Receptors and Epithelial Na+ ChannelsCystic Fibrosis;HealthyDrug: Albuterol;Drug: Placebo salineUniversity of ArizonaNational Heart, Lung, and Blood Institute (NHLBI)Completed15 Years55 YearsAll32N/AUnited States
5NCT01851642
(ClinicalTrials.gov)
September 200725/4/2013Lung Disease and Its Affect on the Work of White Blood Cells in the LungsThe Role of Conformational Diseases on Macrophage FunctionAlpha-1 Antitrypsin Deficiency;AAT Deficiency;AATD;Cystic Fibrosis (CF)Procedure: History and physical exam.;Procedure: Blood draw.;Procedure: Pulmonary function testing.;Drug: Albuterol inhaler.University of FloridaNULLRecruiting18 YearsN/AAll220United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00005110
(ClinicalTrials.gov)
April 200013/4/2000A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic FibrosisCystic FibrosisDrug: Salmeterol;Drug: AlbuterolNational Center for Research Resources (NCRR)NULLSuspended5 Years45 YearsBothN/AUnited States